Evidence map›Paper›PMID 30132277›Full record

ReviewInternational urology and nephrology2018

Cancer survivorship issues with radiation and hemorrhagic cystitis in gynecological malignancies.

Bernadette M M Zwaans, Laura E Lamb, Sarah Bartolone, Heinz E Nicolai, Michael B Chancellor, Stangel-Wójcikiewicz Klaudia

Open access · greenAbstract readReview
In one paragraph

Review in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Bernadette M M ZwaansDepartment of Urology, William Beaumont Hospital, Royal Oak, MI, USA.
Laura E LambDepartment of Urology, William Beaumont Hospital, Royal Oak, MI, USA.
Sarah BartoloneDepartment of Urology, William Beaumont Hospital, Royal Oak, MI, USA.
Heinz E NicolaiDepartamento di Urología, Universidad de Chile, Santiago, Chile.
Michael B ChancellorDepartment of Urology, William Beaumont Hospital, Royal Oak, MI, USA. michael.chancellor@beaumont.org.
Stangel-Wójcikiewicz KlaudiaDepartment of Gynecology and Oncology, Collegium Medicum Jagiellonian University of Kraków, Kraków, Poland.
Beaumont Hospital, Royal Oak · USOakland University · USJagiellonian University · PLUniversity of Chile · CL

Funding

Cancer Survivorship Research and Training in Radiation CystitisK01DK114334 · NIDDK · WILLIAM BEAUMONT HOSPITAL RESEARCH INST · PI ZWAANS, BERNADETTE MARGARETHA MARIA · 2018 to 2020
$444k
National Institute of Diabetes and Digestive and Kidney Diseases K01DK114334NIDDK NIH HHS K01 DK114334
6 · The paper itself

Abstract

purposeGiven that more cancers are being diagnosed earlier and that treatment of cancer is improving, health issues of cancer survivors are becoming more common and apparent. Pelvic radiation therapy for the treatment of gynecological cancers can lead to long-term collateral damage to the bladder, a condition termed radiation cystitis (RC). Late sequelae may take many years to develop and include incontinence and pain as well as hematuria. RC is a rare but potentially life-threatening condition for which there are few management and treatment options.

methodsThere are limited data in the literature regarding the effects of radiation on the bladder after gynecological cancer therapy and we hereby review the literature on cancer survivorship issues of pelvic radiation for gynecology literature.

resultsTreatment options are available for patients with radiation-induced hemorrhagic cystitis. However, most treatments are risky or only effective for a short timeframe and no therapy is currently available to reverse the disease progress. Furthermore, no standardized guidelines exist describing preferred management options. Common therapies include hyperbaric oxygen therapy, clot evacuation, fulguration, intravesical instillation of astringent agents, and surgery. Novel developing strategies include Botulinum Toxin injections and liposomal-tacrolimus instillations. These treatments and strategies are discussed.

conclusionsIn this review, we will present current and advanced therapeutic strategies for RC to help cancer survivors deal with long-term bladder health issues.

Indexed as

Administration, IntravesicalAstringentsBotulinum ToxinsCancer SurvivorsCystitisFemaleGenital Neoplasms, FemaleHematuriaHumansHyperbaric OxygenationImmunosuppressive AgentsRadiation InjuriesSurvivorshipTacrolimusUrinary BladderAstringentsBotulinum ToxinsImmunosuppressive AgentsTacrolimusBladderCancer survivorshipGynecology cancerHemorrhagic cystitisInflammationRadiation cystitis

Identifiers

PMID30132277
PMCPMC6487476
OpenAlexW2888128881

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.